A Phase 2 interventional study of Diosmin and Rebamipide 100mg in Rheumatoid Arthritis (RA), sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Tanta University · Phase 2, Interventional, and Treatment
This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups:
- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months.
- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months.
- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.
2,888 studies on the registry are indexed under Arthritis, Rheumatoid; 390 are open to participants now.
This study's planned enrollment of 66 is below the median of 94 across 1,984 interventional studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
will include 22 patients who will receive the conventional therapy for RA for 3 months.
Drug: Convential medical treatment
will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months.
Drug: Diosmin · Drug: Convential medical treatment
will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.
Drug: Rebamipide 100mg · Drug: Convential medical treatment
1000 mg diosmin once daily for 3 months
100 mg rebamipide three times daily for 3 months
conventional medical treatment for RA
The change in Disease Activity score-CRP (DAS28-CRP)
disease activity will be assessed through: Calculation of 28-joint count Disease Activity Score (DAS28) using C- reactive protein level (CRP) according to the following formula: DAS28-CRP = \[0.56\*√ (tender joint count) + 0.28\*√ (swollen joint count) + 0.36\*ln (CRP+1)\]\*1.10 + 1.15\]
Time frame: At baseline and after three months of the intervention
The change in The Health Assessment Questionnaire-Disability Index (HAQ-DI) score
the functional status of the participants will be assessed through: The Health Assessment Questionnaire-Disability Index (HAQ-DI)
Time frame: At baseline and after three months of the intervention
The change in serum level of C- reactive protein (CRP)
Time frame: three months
The change in serum level of Tumor necrosis factor-alpha (TNF-α)
Time frame: three months
The change in serum level of Matrix metalloproteinase-3 (MMP-3)
Time frame: three months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tanta University